[Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report].
We report a postmenopausal recurrent breast cancer patient with triple negative disease who presented with right recurrent nerve palsy. Nine years previously, she had undergone a mastectomy. FDG-PET scan revealed neck lymph node metastases from the breast cancer. The recurrent nerve palsy was thus considered to have been caused by the lymph node metastases. The patient was orally administered DMpC (doxifluridine, medroxyprogesterone acetate and cyclophosphamide) combination therapy. This resulted in a remarkable response after five months, with the recurrent nerve palsy completely disappearing at six months. No side effects from the treatment were observed. The patient was well and the treatment was being continued without relapse at nine months. Oral anti-cancer treatments such as DMpC appear to have few side effects and might be an effective treatment option for recurrent breast cancer patients with triple negative disease.
Sakurai
Teruhisa
T
Dept. of Surgery, Wakayama Medical University Kihoku Hospital, Japan.
Umemura
Teiji
T
Jinta
Eri
E
Suzuma
Takaomi
T
Yoshimura
Goro
G
Shimizu
Sayuri
S
Sakurai
Takeo
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D005467:Floxuridine / Q000627:therapeutic use*; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed
D005467:Floxuridine; D003520:Cyclophosphamide; D017258:Medroxyprogesterone Acetate; C025034:doxifluridine